Announcements Trials
Browse Landscape

Phase

Phase NA 5Phase 2 2Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Plasma cell 1

Conditions

Neoplasms 1Multiple Myeloma 1

Interventions

Cisplatin 1038Cyclophosphamide 972Carboplatin 952Radiotherapy 890Bevacizumab 845Gemcitabine 817pembrolizumab 758Paclitaxel 738Docetaxel 733Oxaliplatin 704Capecitabine 646Fluorouracil 563Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 400Leucovorin 376Cytarabine 342Cetuximab 338Lenalidomide 326Trastuzumab 321Pemetrexed 314durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 277Temozolomide 275Prednisone 273

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × OTHER × Aging × Clear all
NCT00505063 2025-06-15

Prospective Trial of Vaccine Responses in Childhood Cancer Survivors

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
76 enrolled
Tumor-Agnostic

Neoplasms

NCT00807599 2019-03-15

Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
67 enrolled 12 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡